Literature DB >> 9468021

Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets.

U P Schwarz1, P Plascjak, M P Beitzel, O A Gansow, W C Eckelman, T A Waldmann.   

Abstract

These studies describe the production and purification of 211At as well as the procedure for labeling humanized anti-Tac, the antibody to the alpha-chain of the IL-2 receptor (IL-2R alpha), which has been shown to be a useful target for immunotherapy. The optimized protocol combines the advantages of the two-stage dry distillation procedure with the astatination of trialkylstannyl substances as labeling compounds for proteins. The 211At was produced by bombarding either an external or a recently developed disposable internal bismuth target with alpha-particles from a Cyclotron Corporation CS-30 cyclotron. The 211At was found to contain less than 0.01% 210At. The production rate for the external target was 0.15 mCi +/- 0.056 microA(-1) h(-1) (n = 9) (5.55 MBq mcroA[-1] h[-1]). The production rate for the internal target was 0.44 +/- 0.14 mCi microA(-1) h(-1) (n = 16) (16.28 MBq mcroA[-1] h[-1]).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468021     DOI: 10.1016/s0969-8051(97)00165-0

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  9 in total

Review 1.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

Review 2.  Astatine-211: production and availability.

Authors:  Michael R Zalutsky; Marek Pruszynski
Journal:  Curr Radiopharm       Date:  2011-07

3.  Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.

Authors:  Zhuo Zhang; Meili Zhang; Kayhan Garmestani; Vladimir S Talanov; Paul S Plascjak; Barbara Beck; Carolyn Goldman; Martin W Brechbiel; Thomas A Waldmann
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

4.  Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.

Authors:  Meili Zhang; Zhengsheng Yao; Hiral Patel; Kayhan Garmestani; Zhuo Zhang; Vladimir S Talanov; Paul S Plascjak; Carolyn K Goldman; John E Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

5.  Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Rachel Barkley; Martin W Brechbiel
Journal:  Dalton Trans       Date:  2017-10-31       Impact factor: 4.390

6.  Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.

Authors:  Matthew K Robinson; Calvin Shaller; Kayhan Garmestani; Paul S Plascjak; Kathryn M Hodge; Qing-An Yuan; James D Marks; Thomas A Waldmann; Martin W Brechbiel; Gregory P Adams
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

Review 7.  Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.

Authors:  Sture Lindegren; Per Albertsson; Tom Bäck; Holger Jensen; Stig Palm; Emma Aneheim
Journal:  Cancer Biother Radiopharm       Date:  2020-02-20       Impact factor: 3.099

8.  Investigation of a tellurium-packed column for isolation of astatine-211 from irradiated bismuth targets and demonstration of a semi-automated system.

Authors:  Yawen Li; Donald K Hamlin; Ming-Kuan Chyan; Taylor M Morscheck; Maryline G Ferrier; Roger Wong; D Scott Wilbur
Journal:  Sci Rep       Date:  2019-11-18       Impact factor: 4.379

Review 9.  Production, purification and availability of 211At: Near term steps towards global access.

Authors:  Yutian Feng; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2021-06-10       Impact factor: 2.947

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.